Inclusion Criteria:

          1. The informed consent form (ICF) (genotype and tumor antigen screening and primary
             screening) should be signed before any research related operation;

          2. Age ≥ 18 years and ≤ 70 years;

          3. Advanced solid tumor with definite pathological diagnosis;

          4. Unresectable advanced solid tumor that fails to undergo standard treatment (disease
             progression or recurrence or intolerable, such as chemotherapy, radiotherapy, targeted
             treatment, etc.) or lacks effective treatment:

        1) Soft tissue sarcoma: a) Soft tissue sarcoma failed to be treated by chemotherapy
        containing doxorubicin and ifosfamide; 2) Primary liver cancer: a) Child Pugh liver
        function score A within 7 days before cell reinfusion; 3) Ovarian cancer: a) Platinum based
        chemotherapy (such as paclitaxel combined with carboplatin) failed. 4) Non small cell lung
        cancer (NSCLC): a) failure (disease progression or toxicity intolerance) or lack of
        effective treatment method of previous standard treatment (including platinum chemotherapy
        scheme or driven gene targeted treatment); 5) Breast cancer: a) patients who have received
        standard treatment failure or not applicable standard treatment.

        5、At least 1 measurable lesion (according to recist1.1 standard） 6、Genotype and tumor
        antigen screening must meet the following two criteria: 1) HLA-A * 02:01 positive; 2)
        NY-ESO-1 positive: immunohistochemistry positive cells ≥ 20%; 7、ECOG score 0-1 and expected
        survival time > 3 months; 8. Color Doppler echocardiography indicates left ventricular
        ejection fraction ≥ 50%; 9. Laboratory test results should at least meet the following
        criteria:

          -  White blood cell count ≥ 3.0 × 109 / L

          -  Absolute neutrophil count (ANC) ≥ 1.5 × 109 / L (without the support of G-CSF and
             GM-CSF, at least 14 days before CLT);

          -  Absolute lymphocyte count (ALC) ≥ 0.7 × 109 / L;

          -  Platelet (PLT) ≥ 75 × 109 / L (no transfusion treatment 14 days before CLT);

          -  Hemoglobin ≥ 10g / dl (no transfusion treatment 14 days before CLT);

          -  Prothrombin time international INR ≤ 1.5 × ULN, unless anticoagulant therapy is used;

          -  APTT ≤ 1.5 × ULN, unless anticoagulant therapy is used;

          -  Serum creatinine ≤ 1.5mg/dl (or 132.6 μ mol / L)

          -  Creatinine clearance ≥ 60ml / min;

          -  AST / SGOT ≤ 2.5 × ULN; - ALT / SGPT ≤ 2.5 × ULN; - TBIL ）≤1.5×ULN； 10、Women of
             childbearing age who have not undergone sterilization before menopause must agree to
             use effective contraceptive measures within one year from the beginning of study
             treatment (chemotherapy for clearing lymph nodes) to the end of cell transfusion, and
             the serum pregnancy test is negative within 14 days before the first cell transfusion.

             11、Men who have not undergone sterilization must agree to use effective contraceptive
             measures from the beginning of the study treatment (chemotherapy) until one year after
             the last cell transfusion.

        Exclusion Criteria:

          1. The last dose of anti-tumor therapy (chemotherapy, endocrine therapy, targeted
             therapy, immunotherapy, tumor embolization or traditional Chinese medicine / Chinese
             herbal medicine with anti-tumor indications) was received within 4 weeks before cell
             reinfusion;

          2. The live attenuated vaccine had been inoculated within 4 weeks before cell reinfusion;

          3. The patients with bone metastasis in the whole body;

          4. It is known that any component used in the treatment of this study will produce
             allergy Response;

          5. Not recovered from previous operation or treatment-related adverse reactions to <
             2-level CTCAEv5.0;

          6. Patients with a history of meningeal or central nervous system metastasis, or patients
             with clear basic diseases of central nervous system and left significant symptoms
             within 6 months before cell transfusion;

          7. Patients with poor drug control hypertension (systolic blood pressure > 160mmhg and /
             or diastolic blood pressure > 90mmHg) or with clinical significance Cardiovascular and
             cerebrovascular diseases, such as cerebrovascular accident (within 6 months prior to
             signing the master informed consent), myocardial infarction (within 6 months prior to
             signing the master informed consent), unstable angina pectoris, congestive heart
             failure with NYHA grade II or above, or serious arrhythmia that cannot be controlled
             by drugs or has potential impact on research and treatment Results of ECG showed
             clinically significant abnormality or average QTCF ≥ 450ms;

          8. Combined with other serious organic or mental diseases;

          9. Suffering from systemic active infection requiring treatment, including but not
             limited to active tuberculosis, known HIV positive patients or clinical active
             hepatitis A, B and C Patients with inflammation, including virus carriers, should be
             excluded;

         10. Patients with autoimmune diseases: those with inflammatory bowel disease history and
             those with autoimmune disease history determined by the researchers as unsuitable for
             this study, such as systemic lupus erythematosus, vasculitis, and invasive lung
             disease, should be excluded (except vitiligo subjects);

         11. Those with cell transfusion within 4 weeks before and during the study should be used
             (if there is a long-term plan) Use) systemic sterols, hydroxyurea, immunomodulators
             (e.g., interferon α or γ, GM-CSF, mTOR inhibitors, cyclosporin, thymosin, etc.);

         12. History of organ transplantation, allogeneic stem cell transplantation, and renal
             replacement therapy;

         13. Diabetes, pulmonary fibrosis, interstitial lung disease, acute lung disease, or liver
             failure that are not known to be controlled;

         14. Alcohol and / or drug abusers;

         15. Pregnant or lactating women;

         16. Subjects with any coexisting medical conditions or diseases that may affect the
             development of this study determined by the investigator;

         17. Subjects without legal capacity / limited capacity of behavior;

         18. Patients who have received similar gene therapy products within 4 weeks before cell
             reinfusion and are not suitable for inclusion by evaluation;

         19. Patients judged by the investigator are difficult to complete all visits or procedures
             required by the protocol (including the follow-up period), or insufficient compliance
             to participate in the study, or the patients considered unsuitable by the
             investigator.